Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study
Sign Up to like & getrecommendations! Published in 2019 at "OncoTargets and therapy"
DOI: 10.2147/ott.s182259
Abstract: Background In RADIANT-4, everolimus showed an improvement of 7.1 months in median progression-free survival (PFS) vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin. The present analysis… read more here.
Keywords: east asian; analysis; everolimus; nonfunctional neuroendocrine ... See more keywords